Reduction In Workforce

12 Months Ended

Dec. 31, 2012

Reduction In Workforce [Abstract]

Reduction In Workforce

Note 12 — Reduction in Workforce

In March 2012, the Company implemented a reduction in its workforce of 11 full-time employees, primarily in research and development that were included in the Company’s Rest of the World (including the US) segment. The restructuring follows the discontinuation of the Company’s SCV-07 phase 2b clinical trial. The reduction in workforce resulted in severance-related charges of approximately $1.1 million, of which $0.1 million and $1.0 million was recognized in general and administrative and research and development expense, respectively, in the consolidated statement of income for year ended December 31, 2012. As of December 31, 2012, the Company had paid $0.9 million and had accrued $0.2 million of the severance-related charges. The Company had substantially completed its restructuring activities as of December 31, 2012.